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Cytochrome c oxidase (COX) deficiency is a frequent biochemical abnormality in mitochondrial disorders, but a large fraction of cases
remains genetically undetermined. Whole-exome sequencing led to the identification of APOPT1mutations in two Italian sisters and in
a third Turkish individual presenting severe COX deficiency. All three subjects presented a distinctive brainMRI pattern characterized by
cavitating leukodystrophy, predominantly in the posterior region of the cerebral hemispheres. We then found APOPT1 mutations in
three additional unrelated children, selected on the basis of these particular MRI features. All identified mutations predicted the synthe-
sis of severely damaged protein variants. The clinical features of the six subjects varied widely from acute neurometabolic decompensa-
tion in late infancy to subtle neurological signs, which appeared in adolescence; all presented a chronic, long-surviving clinical course.
We showed that APOPT1 is targeted to and localized within mitochondria by an N-terminal mitochondrial targeting sequence that is
eventually cleaved off from the mature protein. We then showed that APOPT1 is virtually absent in fibroblasts cultured in standard con-
ditions, but its levels increase by inhibiting the proteasome or after oxidative challenge. Mutant fibroblasts showed reduced amount of
COX holocomplex and higher levels of reactive oxygen species, which both shifted toward control values by expressing a recombinant,
wild-type APOPT1 cDNA. The shRNA-mediated knockdown of APOPT1 in myoblasts and fibroblasts caused dramatic decrease in cell
viability. APOPT1 mutations are responsible for infantile or childhood-onset mitochondrial disease, hallmarked by the combination
of profound COX deficiency with a distinctive neuroimaging presentation.Cytochrome c oxidase (COX, complex IV [cIV], E.C.
1.9.3.1) is the terminal component of the mitochondrial
respiratory chain (MRC), operating the electron transfer
from reduced cytochrome c to molecular oxygen. The
redox reaction is coupled with proton translocation across
the inner mitochondrial membrane, thus contributing to
the formation of the mitochondrial membrane electro-
chemical potential (DJ). DJ is eventually utilized by the
F1F0-ATP synthase (complex V) to produce ATP, the univer-
sal energy currency of the cell. Human COX is composed
of several subunits:1,2 the three largest are encoded by
mitochondrial DNA (mtDNA) genes and form the catalytic
core of the enzyme. The remaining 11 nuclear-encoded
subunits, some of which have tissue-specific isoforms,3
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The AmericanCOX deficiency (MIM 220110) is one of the most com-
mon biochemical abnormalities found in mitochondrial
disorders, but about half of all cases remain genetically
undefined.4 Mutations in mtDNA or nuclear DNA genes
encoding COX subunits are exceptionally rare, suggesting
that direct damage of the structural components of cIV
is likely to cause embryonic lethality in most cases.
Conversely, early-onset COX deficiency is often due tomu-
tations in assembly factors of the enzyme,5 SURF1 (MIM
185620) being the most commonly affected gene.6,7
SURF1 mutant individuals typically present with Leigh
syndrome (LS), an early-onset, rapidly progressive enceph-
alopathy characterized by bilateral focal necrotizing
lesions in the basal ganglia and brainstem nuclei. In addi-
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Figure 1. MRI Findings
(A) MRI abnormalities observed in individual S6 in the acute stage at the age of 3 years. The sagittal image shows signal abnormalities in
the posterior part of the corpus callosum and a single lesion at the genu (red arrows in A1). Axial T2-weighted (A2, red arrows), FLAIR
(A3), and T1-weighted (A4) images show signal abnormalities predominantly involving the posterior part of the cerebral white matter
and corpus callosum with numerous small and larger, well-delineated cysts. The diffusion-weighted images show that the noncavitated
abnormalities have a high signal, suggesting diffusion restriction (red arrows in A5), as confirmed by the low signal on the apparent diffu-
sion coefficient (ADC) maps (red arrows in A6).
(B) MRI abnormalities observed in individual S4 in the subacute stage at the age of 5 years. The sagittal image shows the involvement of
the posterior part of the corpus callosum (red arrow in B1). Axial T2-weighted (B2), FLAIR (B3), and T1-weighted (B4) images show signal
abnormalities predominantly involving the posterior part of the cerebral white matter and corpus callosum with numerous small, well-
delineated cysts. Additional minor abnormalities are seen next to the anterior horn of the lateral ventricle on the right (red arrows in B2
(legend continued on next page)
316 The American Journal of Human Genetics 95, 315–325, September 4, 2014
expression or translation are consistently associated with
isolated or predominant COX deficiency,8–11 including
some mutations in mitochondrial tRNA-encoding genes
or in nuclear-encoded mtDNA translation proteins (e.g.,
LRPPRC [MIM 607544] or several mitochondrial aminoacyl
tRNA synthetases). As part of a long-standing project
aimed at identifying novel genes responsible for COX defi-
ciency, we present here the identification of deleterious
mutations in APOPT1 (Apoptogenic-1, previously APOP-1
or C14ORF153), encoding a mitochondrial protein. This
gene was identified by whole-exome sequencing (WES)
analysis in three individuals from independent cohorts
of subjects with isolated COX deficiency and subsequently
in three additional unrelated children on the basis of a
distinctive brain MRI pattern present in all.
Informed consent for participation in this study was
obtained from the parents of all investigated subjects, in
agreement with the Declaration of Helsinki and approved
by the Ethical Committees of the Centers participating in
this study, where biological samples were obtained.
A total of six individuals from five families were found
to harbor mutations in APOPT1 (see below). The clinical
features varied widely from acute neurometabolic decom-
pensation in late infancy to subtle neurological signs pre-
senting in adolescence. Encephalopathic episodes were
characterized by acute loss of developmental milestones
including ability to walk or sit, loss of speech, episodes
with somnolence and seizure, and pyramidal signs rapidly
evolving into spastic tetraparesis. In all cases, the clinical
course subsequently tended to stabilize and in several sub-
jects marked recovery of neurological milestones was
observed over time. Brain MRI was characterized by a cavi-
tating leukodystrophy, predominantly involving the pos-
terior cerebral white matter and the corpus callosum in
the acute stage, after which the abnormalities partially
improved and then stabilized (Figure 1). A summary of
the clinical features is presented in Table 1 (for further de-
tails contact the corresponding authors). The MRI features
are summarized in Table S1 available online and a detailed
description is provided in the legend of Figure 1.
Histological examination12 of muscle biopsies from indi-
vidual S1, taken at 2.5 years, and from individual S2, taken
at 7 months of age, demonstrated diffuse, profound reduc-
tion of histochemical COX reaction (Figures 2A and 2B),
compared to a control muscle (Figure 2C). EM studies on
the muscle biopsy from individual S1 showed the presence
of enlarged mitochondria with osmiophilic inclusions and
disorganization of the cristae (Figures 2D, S1A, and S1B).
Biochemical analysis of individual MRC complex activ-
ities13 of individual S1 muscle homogenate showed thatand B4). After contrast, enhancement of multiple foci is seen (red arro
of high signal, suggesting diffusion restriction (red arrows in B5), as
Follow-upMRI of the same subject (B7–B10) shows striking improvem
is now visible (red arrows in B9 and B10).
(C) Late follow-up MRI of individual S1 at age 21 shows atrophy and
some small cysts in the abnormal white matter (C2).
(D) MRI of individual S2 shows only minor posterior cerebral white
The AmericancIV activity, normalized to citrate synthase (CS), was 20%
of the mean normal value in muscle and 61% in fibro-
blasts. A partial decrease in complex II activity (cII/CS)
was also noted in muscle (44%) and fibroblasts (58%);
however, spectrophotometric succinate dehydrogenase
(SDH) activity was normal in both tissues and the histo-
chemical SDH reaction in muscle was also normal (Figures
S1C and S1D). The SDH reaction in the individual S2
muscle biopsy was normal as well (Figures S1E and S1F).
Biochemical assay of individual S2 muscle homogenate re-
vealed marked increase of CS activity in muscle homoge-
nate, resulting in reduced values of all the respiratory chain
activities when normalized to CS. Nevertheless, cIV/CS
showed the most severe defect in muscle (3% of the con-
trols’ mean). Additionally, a partial decrease of cII/CS and
cIV/CS activities was detected in fibroblasts. Histochemical
and biochemical analyses of a muscle biopsy from individ-
ual S3 performed at age 10 years showed profound COX
deficiency, with a residual cIV/CS activity of 5% of the con-
trols’ mean (Figures S2A and S2B, Table 2); fibroblasts were
not available for further study. In muscle and fibroblasts
obtained from individual S4 at 5 years, a severe decrease
in cIV/CS activity (8% and 25%, respectively) was found.
Individual S6 muscle biopsy taken at 2 years showed
diffuse reduction of COX histochemical activity (Figures
S2C and S2D), and spectrophotometric analysis of respira-
tory chain enzymes showed isolated cIV/CS defect (36% of
the control mean). Furthermore, the histochemical reac-
tion to COX was dramatically decreased in S6 fibroblasts
(Figure 2E) compared to a control cell line (Figure 2F). A
summary of the MRC activities is provided in Table 2 for
all cases with the exception of individual S5 who did not
undergo investigative muscle or skin biopsies.
Mutations in SURF1 and mtDNA were excluded in indi-
viduals S1, S3, S4, and S6. Southern blot analysis showed
no deletion or depletion of individual S1 muscle mtDNA,
although the elevated CS activity in individual S2 muscle
was accompanied by a 3-fold increase in mtDNA con-
tent14 compared to age-matched control muscle specimens
(not shown). WES was subsequently performed on DNA
from individuals S1 and S2;15 after filtering steps to exclude
common SNPs (frequency > 0.2%), we searched for homo-
zygous or compound heterozygous variants shared by the
two sisters, according to a predicted recessive mode of
inheritance. From the list of genes prioritized by this
procedure, we then selected (1) variants known to be asso-
ciated with MRC defects and (2) novel recessive variants
affecting genes that encode known or predicted mitochon-
drial proteins.15 As a result, a homozygous variant was
identified in APOPT1, a gene on chr14q32.33 (Table 3,ws in B4). The diffusion-weighted images showmultiple small foci
confirmed by the low signal on the ADC maps (red arrows in B6).
ent (B7 and B8). Involvement of long tracts within the brain stem
gliosis of what is remaining of the cerebral white matter (C1) with
matter abnormalities at age 15 (D1) with tiny cysts (D2).
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Table 1. Clinical Features
Affected Subject S1 S2 S3 S4 S5 S06
Gender female female male male male female
Year of birth 1987 1998 1997 2000 2007 2009
Siblings (affected /
unaffected / otherwise
affected)
1 / 0 / 0 1 / 0 / 0 0 / 1 / 0 0 / 1 / 0 0 / 8 / 0 0 / 1 / 0
Consanguinity
parents
  þ þ þ 
Pregnancy, delivery,
neonatal period
normal normal normal normal normal normal
Initial motor &
cognitive
development
normal normal normal normal mildly delayed normal
Single Episode of Regression
Age at presentation
(years)
2.5 never developed
neurological
signs
3 5 5 2
Signs at presentation L-hemiparesis,
somnolence,
irritability, loss
of ambulation
NA delayed speech,
gait difficulties
gait difficulties dysarthria and gait
difficulties
frequent falls and
leg weakness
Preceding event recurrent vomiting
and poor growth
NA NA NA febrile illness febrile illness
Signs of regression severe spastic
tetraparesis,
lowered
consciousness
NA spastic tetraparesis
L > R
spastic tetraparesis,
ataxia and
sensorimotor
polyneuropathy
with loss of
unsupported
walking
spastic tetraparesis,
ataxia and
sensorimotor
polyneuropathy
with loss of
unsupported
walking
spastic tetraparesis
and sensorimotor
polyneuropathy
with loss of
ambulation;
gastrostomy due to
swallowing defect
Treatment temporary
improvement on
steroids; riboflavin,
coenzyme Q10,
thiamine and
vitamin C
coenzyme Q10,
carnitine and
vitamin C
none none none riboflavin,
coenzyme Q10
Duration of regression 2 months NA 2 years 2–3 months 2–3 months 5 months
Further regressions seizures at age 4,
controlled with
carbamazepine; no
further regression
NA a somnolence
episode with
generalized seizure
at age 5; 3 seizures
during follow-up
of 11 years; no
further regression
no further
regression
no further
regression
no further
regression
Outcome
Age (years) 26 14 16 13 6.5 4
Motor function wheelchair-bound normal moderate spastic
tetraparesis L > R;
wheelchair-bound
walks, mild signs
of spasticity, ataxia,
and peripheral
neuropathy
walks, mild signs
of spasticity, ataxia,
and peripheral
neuropathy
walks, spastic gait
Cognitive level decreased normal decreased slightly decreased normal normal
Speech and language single words,
marked dysarthria
normal dysarthria normal normal normalFigures 3A–3C). The c.235C>T (RefSeq accession number
NM_032374.3) nucleotide substitution is predicted to
introduce a stop codon causing the synthesis of a trun-
cated protein (p.Arg79*; RefSeq NP_115750.2). This mu-
tation was confirmed by Sanger sequencing in both318 The American Journal of Human Genetics 95, 315–325, Septembindividuals S1 and S2, and the parents were shown to be
heterozygous carriers.
WES was independently performed on individual S3,
identifying a nucleotide change c.1631G>A (chr14:
104,037,959 G>A) in APOPT1 by the same filteringer 4, 2014
Figure 2. Morphological Findings
(A–C) The histochemical reaction to COX
is diffusely decreased in muscle biopsies
of individual S1 (A) and individual S2 (B),
compared to a control biopsy (C). Scale
bars represent 100 mm.
(D) Electronmicroscopy of muscle from in-
dividual S1 shows abnormal mitochondria
with osmiophilic inclusions and cristae
disarray. Scale bar represents 0.3 mm.
(E and F) Profound decrease of COX histo-
chemical reaction is also visualized in fi-
broblasts from individual S6 (E) compared
to a control cell line (F). Scale bars repre-
sent 10 mm.strategy (Table 3, Figures 3A–3C). This variant is within the
conserved consensus splice acceptor site of intron 1. Using
muscle-derived individual S3 cDNA to study APOPT1 tran-
scripts, we showed that exon 2 is completely skipped in
the majority of transcripts, predicting the maintenance
of the open reading frame for the synthesis of a 140-
amino-acid-long species lacking approximately one-third
of the wild-type protein (p.Val55_Lys120del). Low-level
transcripts appeared to show partial retention of intron 1
(c.162þ91_162þ255) (Figure S3). No trace of normal
APOPT1 mRNA was detected by this analysis.
We then sequenced APOPT1 in five subjects character-
ized by cavitating leukoencephalopathy with posterior
predominance, and found mutations in three individuals
(S4, S5, and S6). Individuals S4 and S6 presented with se-
vere COX deficiency whereas individual S5 was not inves-
tigated biochemically. Additional subjects with isolated
cIV deficiency with or without unspecific leukoencephalo-
pathic changes (n ¼ 10) were also screened, but no further
mutations were identified.
PCR amplification of exon 3 ofAPOPT1was unsuccessful
using genomic DNA from individual S4 (Figure S4A),
suggesting a homozygous deletion of the corresponding
genomic region, and no mutation was identified in other
exons. Since we successfully generated PCR products of
exons 2 and 4, we assume that the deletion does not
extend beyond 15,328 bp, corresponding to the distance
between oligonucleotide primers 2R and 4F. Accordingly,
analysis of the cDNA retrotranscribed from the mutant
transcript showed the absence of the mRNA portion en-
coded by exon 3 (Figures S4B and S4C). The deletion of
exon 3 causes a change in the reading frame of APOPT1
and is predicted to result in the introduction of a prema-
ture stop codon (p.Glu121Valfs*6). In individual S5, we
found a homozygous c.353T>C mutation transition, pre-
dicting a p.Phe118Ser substitution. Phe118 is highly
conserved, with mutation to a serine residue being pre-
dicted as extremely deleterious by several bioinformatics
tools (Figure S5). In individual S6, we identified two hetero-
zygous mutations: the same c.235C>T change present in
individuals S1 and S2 and a three-nucleotide deletionThe American(c.370_372delGAA) causing the elimination of a highly
conserved amino acid residue (p.Glu124del). Parents
were shown to be heterozygous carriers of one mutation,
and a healthy sibling was heterozygous for the nonsense
mutation. Details of the APOPT1 mutations and corre-
sponding changes in the protein are summarized in Fig-
ure 3A and Table 3.
APOPT1 is predicted to be a mitochondrial protein
possessing an N-terminal mitochondrial targeting signal
(MTS) (Figure S6A). Two putative ATG start codons are pre-
sent in the open reading frame NM_032374.3, encoding
methionines at positions 1 and 14; however, the predicted
mature forms of APOPT1 precursors starting from Met1
(APOPT1-M1) orMet14 (APOPT1-M2) are the same, because
cleavage ispredicted tooccurbetweenaminoacids39and40
(Figure S6B). GFP-tagged recombinant murine APOPT1 was
previouslydemonstrated tohavemitochondrial localization
when transiently expressed in cultured cells.16 Using suit-
able recombinant constructs inserted into lentiviral vectors
(pLenti6.3/V5-TOPOvector system, Invitrogen),we showed
that both the humanGFP-taggedAPOPT1-M1 andAPOPT1-
M2 proteins colocalize with a mitochondrial marker (Mito-
tracker red) when transiently transduced in fibroblast cells
(Figures 3D and S6C). However, we considered the 193-
amino-acid sequence starting from M14 as the most likely
human APOPT1 protein, for two reasons. First, although
the APOPT1 sequence is conserved in animals, M1 is absent
in all species except primates (Figure S6B). Second, the hu-
man APOPT1 transcript (RefSeq NM_032374.3) has only
one nucleotide in the 50 UTR upstream of the first AUG,
and it is known that ribosomesdonot recognize start codons
that are less than 12–20 nucleotides downstream of the cap
structure in the 50 UTR. Therefore, we used APOPT1-M2
(named APOPT1 hereafter) for all further experiments.
We tested diverse commercial antibodies against human
APOPT1 (Abcam, Santa Cruz) but none showed clear
immunoreactivity by either immunoblot or immunofluo-
rescence. We therefore created a lentiviral vector encoding
a recombinant human APOPT1 protein tagged with
the 9-amino-acid-long HA epitope at the C terminus
(APOPT1-HA). Using an anti-HA monoclonal antibody,Journal of Human Genetics 95, 315–325, September 4, 2014 319
Table 2. Mitochondrial Respiratory Chain Activities
Subject cI/CSa cII/CSa cIII/CSa cIV/CSa CSb
Muscle
biopsy
S1 142 44* 91 20* 90
S2 47* 11* 32* 3* 374*
S3 140 69 93 5* 119
S4 58 100 42* 8* 29*
S6 127 81 132 36* 100
Skin
biopsy
S1 128 58 105 61 101
S2 56 54* 82 50* 147
S4 58 98 104 25* 150*
The analyses were performed in different laboratories, and the reference values
are diverse (usually ranging between 60% and 150% of the mean control
value). The values out of the control range (specific for each enzymatic activity
and for each laboratory) are indicated with an asterisk (*).
aPercent of mean control value of MRC complexes/citrate synthase (CS)
activities.
bPercent of mean control value.we performed immunoblot analysis on lysates of tran-
siently transduced HeLa cells.17 We detected two faint
immunoreactive bands with the same electrophoretic
mobility of the in vitro synthesized17 putative APOPT1-
HA precursor (193þ9 amino acids, predicted MW
24 kDa) and mature (167þ9 amino acids, predicted MW
20 kDa) species (Figure S6D). These results confirm that hu-
man APOPT1 has an N-terminal mitochondrial targeting
sequence (MTS) of ~4 kDa, which is cleaved from the
mature protein species following import into the inner
mitochondrial compartment.
In order to study the effect of the protein in a cellular
system, we attempted to examine APOPT1-HA in HeLa
and fibroblast cell lines, by transducing a recombinant
lentiviral expression construct that requires puromycin
as a selectable marker.17 Although we detected high levels
of recombinant APOPT1-HA transcript after selection
(Figure S7A), hardly any protein was immunovisualized
by immunoblot or immunofluorescence in either trans-
duced cell line. To test whether this result was due to selec-
tive APOPT1-HA-induced cell death, we used a Tet on-off
inducible vector, expressing the APOPT1-HA transcript un-
der exposure to increasing concentrations of doxycycline.
However, we were unable to detect the protein in doxycy-
cline-treated cells expressing high levels of the APOPT1-HA
transcript (Figure S7B) and failed to observe increased
cell death in induced compared to control cells. Taken
together, these results indicate that the APOPT1-HA
cDNA is expressed transcriptionally, but the corresponding
protein product is rapidly degraded by a surveillance sys-
tem active in standard culturing conditions. To further
explore this hypothesis, immortalized fibroblasts from
either individual S2 or a control subject, stably transduced
with the APOPT1-HA lentiviral vector, were treated with
MG-132 (5 mM for 24 hr), a proteasome inhibitor.18 HA-
immunoreactive bands corresponding to the precursor320 The American Journal of Human Genetics 95, 315–325, Septemband mature APOPT1-HA species were clearly present in
both MG-132-treated cell lines, in contrast with the
absence of HA-immunoreactive band in the same cell lines
under naive, untreated conditions (Figures 4A and 4B).
These results strongly suggest that APOPT1 precursor
protein is degraded by the proteasome system in standard
culture conditions. Next, we tested whether the levels of
the APOPT1 protein responded to oxidative19 or apopto-
genic20 challenges. We exposed the same transduced cell
lines to increasing concentrations of H2O2 (100 mM–
1 mM) or to a standard concentration of staurosporine
(1 mM), an inducer of apoptosis. Under conditions of
oxidative stress (H2O2 treatment), APOPT1-HA protein
increased to immunodetectable levels, with a maximum
at 24 hr (Figure 4C); no protein was detected following
treatment with staurosporine (data not shown). In contrast
to the effect of MG-132, exposure to H2O2 determined the
predominant accumulation of the mature, intramitochon-
drial, presumably active APOPT1-HA species (Figure 4C).
To test the role of APOPT1-HA stabilization under oxi-
dative stress, we measured the production of reactive oxy-
gen species (ROS) using a dichlorofluorescein-based assay.
While in basal conditions ROS levels were comparable
between immortalizedmutant S2 fibroblasts and control fi-
broblasts, after H2O2 incubation (100 mMor 1mM for 3 hr)
ROS levels in mutant S2 were higher than in control fibro-
blasts (Figure 4D). However, in S2 fibroblasts transduced
with APOPT1-HA-expressing lentiviral vector, the amount
of ROS was decreased with either treatment, being compa-
rable to that found in control cells treated with the higher
H2O2 concentration, suggesting a role for APOPT1 in mito-
chondrial response to ROS (Figure 4D).
Conversely, we obtained no clear evidence of a proa-
poptotic role for APOPT1 in available tissues (muscle, fi-
broblasts): a TUNEL assay was negative on muscle from
individuals S1 and S2, no apoptotic bodies were observed
by EM in individual S1 muscle, and no difference in
apoptotic cells was found after staurosporine treatment
inmutant versus control fibroblasts (not shown). However,
we cannot exclude a selective apoptotic activation in other
tissues/organs, for instance in brain white matter.
We then investigated the amount and integrity of the
COX holocomplex by Blue-Native Gel Electrophoresis
(BNGE) immunoblot analysis17 of dodecylmaltoside-
treated S1 and S2 fibroblasts. We found that the amount
of both COX holocomplex and cIII2þcIV supercomplex
was clearly reduced in both mutant cells, more markedly
in S2 (Figure 5A). The intensities of the bands correspond-
ing to other individual MRC complexes, including cII,
were comparable to controls. The cIV reduction was
confirmed in immortalized fibroblasts from individual S2.
In spite of the very low levels of recombinant APOPT1 in
transduced individual S2 immortalized fibroblasts, we
found a small but consistent increase in the amounts of
cIV and supercomplex cIIIþcIV in these cells compared
to naive individual S2 cells (Figures 5B and 5C), suggesting
a role for APOPT1 in cIV assembly and/or stability.er 4, 2014
Table 3. APOPT1 Mutations
Subject
Country
of Origin
Mutationsa
DNA Protein State Father/Mother SNP Frequencyb
S1c Italy c.235C>T p.Arg79* homo F&M hetc Ø
S2c Italy c.235C>T p.Arg79* homo F&M het Ø
S3 Turkey c.1631G>A Ex2 skipping;
p.Val55_Lys120del
homo NA Ø
S4 Morocco Ex3 deletion Ex3 deletion;
p.Glu121Valfs*6
homo NA NA
S5 Oman c.353T>C p.Phe118Ser homo F&M het Ø
S6 Italy c.235C>T p.Arg79* het M het Ø
c.370_372del p.Glu124del het F het Ø
Abbreviations are as follows: F, father; M, mother; homo, homozygous; het, heterozygous; NA, not available; Ø, not reported variant.
aNomenclature according to HGVS; reference cDNA sequence: RefSeq NM_032374.3.
bFrequency in dbSNP and EVS (Exome Variant Server) databases.
cS1 and S2 are sisters.RNAi experiments were performed by lentiviral trans-
duction of different shRNA sequences targeting the
APOPT1 mRNA (MISSION shRNA Library, Sigma). Cells
transduced with the ‘‘empty’’ pLKO.1 vector were used as
a control. Two shRNAs (shRNA-2 and shRNA-3) produced
marked knockdown of APOPT1 expression in different
cell lines, having <10% of the control mRNA levels (Fig-
ures 5D and S8A). Primary myoblasts and immortalized
control fibroblasts expressing shRNA-2 and shRNA-3
showed a dramatic decrease in cell viability around
5 days after the lentiviral infection (Figure 5E), while the
cells transduced with the control vector were totally viable
in selective medium. No shRNA-3 myoblasts remained af-
ter puromycin selection; surprisingly, however, the cells
transduced with shRNA-2 that did survive failed to show
reduction in COX activity or in the amount of the holo-
complex (Figures S8B and S8C), and ROS levels were not
modified in shRNA fibroblasts compared to controls
(Figure S8D), either before (48 hr) or during (96 hr) the
decline of cell growth.
Our work has relevant implications in the clinical defini-
tion of mitochondrial disorders and in the discovery of
new mitochondrial homeostatic pathways. In six subjects
belonging to five unrelated families, we identified five
mutant alleles in APOPT1, encoding a mitochondrial pro-
tein of unknown function. All mutations are predicted to
result in the synthesis of severely damaged protein species,
due to premature stop,microdeletion,macrodeletion, aber-
rant splicing, or nonconservative substitution of an evolu-
tionary invariant amino acid. In the five subjects for whom
the histoenzymatic and biochemical characterization of
the mitochondrial respiratory chain was possible, we do-
cumented a profound defect of COX activity, associated,
in available cultured fibroblasts, with marked reduction
of cIV holocomplex and cIIIþcIV supercomplex species.
In two siblings, a concomitant, partial reduction of cII/CS
activity was also detected, which was not present in avail-
able samples from the other subjects, suggesting a second-The Americanary effect. APOPT1 mutations were consistently associated
with a peculiar brain MRI pattern characterized by early
and rapid onset of cavitating white matter abnormalities,
predominantly in the posterior areas of the cerebral hemi-
spheres and corpus callosum. This pattern was specific
enough to suggest the direct screening of APOPT1 in a se-
ries of five subjects with cavitating leukodystrophy, three
of whom proved to harbor recessive mutations in this
gene. Interestingly, the two subjects without APOPT1
mutations did not show COX deficiency in fibroblast or
muscle samples. Taken together, these results indicate
that mutations in APOPT1 are responsible for a mitochon-
drial disorder characterized by marked COX deficiency and
a well-characterized form of cavitating leukodystrophy.
MRI hallmarks in the acute stage are white matter abnor-
malities containing numerous small, well-delineated cysts,
predominantly in the posterior areas of the cerebral hemi-
spheres, also involving the connecting corpus callosum. In
severe cases, the white matter abnormalities extend into
the frontal and temporal lobes as well as the anterior part
of the corpus callosum. In the acute stage, multifocal areas
on restricted diffusion and contrast enhancement are
present, and within the abnormal white matter levels of
lactate are high, as revealed by proton magnetic resonance
spectroscopy. Posterior fossa structures are typically spared.
On follow-up, atrophy of the affected areas, collapse of
cysts, and disappearance of diffusion restriction and
contrast enhancement occur, with a concomitant decrease
in lactate levels.
In contrast to other neurological conditions defined by
profound cIV impairment, such as rapidly progressive
SURF1-deficient LS,4 the clinical course of APOPT1-associ-
ated encephalopathy appears to be highly variable in
severity. Although some individuals developed severe
neurological signs at an early age, with motor impairment
evolving into spastic quadriparesis, epilepsy, and severe
cognitive impairment (e.g., individual S1), others showed
an intermediate phenotype with severe motor impairmentJournal of Human Genetics 95, 315–325, September 4, 2014 321
Figure 3. APOPT1 Mutations and
APOPT1 Localization
(A–C) Mutations found in this study are
positioned (arrows) against schematic rep-
resentations of APOPT1 (A), cDNA (B),
and protein (C).
(D) The green fluorescence pattern of an
APOPT1-GFP fusion protein starting from
the methionine 14, transiently expressed
in control fibroblasts (center), coincide
with that obtained with mitotracker red
(left), to give a yellow overlay pattern
(right). Scale bar represents 10 mm.but mild or absent cognitive involvement, and in one case
the neurological examination was virtually normal at 14
years of age (individual S2), despite the presence of some
posterior white matter abnormalities. Strikingly, in all
affected individuals who underwent electromyography
and nerve conduction velocity studies, evidence of a pe-
ripheral neuropathy was also found, even in absence of
clinical signs. Remarkably, severely affected individual S1
and subclinically affected individual S2 are siblings,
sharing the same homozygous mutation, which predicts
the synthesis of a truncated protein, again supporting
the wide clinical variability of this condition. Irrespective
of the severity of the onset and initial evolution, in all cases
both the MRI lesions and the clinical progression stabilize,
determining a chronic, long-surviving clinical course, in
contrast with the rapidly downhill, often fatal outcome
of other early-onset COX-defective encephalopathies.
All our APOPT1 mutant subjects are alive, some in their
teens, with the oldest one being in her third decade. In
some cases stabilization and improvement (individuals
S1 and S6) coincided with the starting of vitamin and/or
CoQ10-based treatment, and in individual S2 the adminis-
tration of a vitamin cocktail since the first months of life
may have helped to prevent the development of clinical
symptoms. Nevertheless the efficacy of these therapies re-
mains unproven, since other subjects (individuals S3, S4,
and S5) showed stabilization with no specific treatment
(Table 1).
Although white matter involvement can be an as-
sociated feature of LS, ‘‘pure’’ (predominant or exclusive)
leukodystrophy encompasses a substantial fraction of
infantile mitochondrial encephalopathies, ranging from
10% to 50% of the cases in different cohorts.21–23 In
some cases, specific MRI leukodystrophic patterns are
consistently associated with mutations in specific genes
related to mitochondrial function, notably a number of
mitochondrial aminoacyl tRNA synthetases including
DARS224 (MIM 610956), EARS225 (MIM 612799), and
more recently AARS211 (MIM 612035).322 The American Journal of Human Genetics 95, 315–325, September 4, 2014APOPT1 was identified in 2006 as a
new/unreported transcript in a study
on murine vascular smooth muscle
cells (VSMCs) cultured from athero-
sclerotic plaques. The gene encodes amitochondrial protein deemed as a proapoptotic factor
because its overexpression induced PTP-dependent apo-
ptotic cell death,16 which could be prevented by activating
the Akt pathway.26 No further published studies on this
protein are available. Our experiments confirmed that
APOPT1 is targeted to and localized within mitochondria.
Absence of a predicted transmembrane domain and pres-
ence of a cleavable N-terminal MTS, which serves for active
translocation across the inner mitochondrial membrane,
suggest that APOPT1 is specifically localized in the mito-
chondrial matrix.
In contrast with previous studies, we obtained no clear
evidence of a proapoptotic role for this protein. We
observed no difference between mutant subjects and con-
trols in both TUNEL assay in muscle and apoptotic induc-
tion with staurosporine in fibroblasts, and no massive
cell death followed transient overexpression of recombi-
nant APOPT1-HA in either HeLa cells or fibroblasts. The
extremely low levels of recombinant APOPT1-HA obtained
in cells grown in standard conditions, despite high levels of
recombinant transcripts detected by quantitative PCR, sug-
gest active degradation of the protein precursor, possibly
via the proteasomal system. This hypothesis was supported
by the stabilization of the precursor APOPT1-HA protein in
recombinant cells exposed to a proteasome inhibitor.
Oxidative challenge with H2O2 of APOPT1-HA-express-
ing recombinant fibroblasts led to a prolonged increase
in the amount of the mature protein species, suggesting
a role for APOPT1 in mitochondrial anti-ROS defense
mechanisms. In order to further test this hypothesis, we
showed that APOPT1-deficient fibroblasts from individual
S2 producemore ROS, whereas overexpression of wild-type
APOPT1 leads to a reduction of ROS. We hypothesize that
APOPT1 is induced by and plays a protective role under
oxidative stress conditions, but it must be otherwise elim-
inated in standard conditions, at least in cultured cells. A
similar mechanism has been demonstrated for other pro-
teins acting at checkpoints in mitochondrial execution
pathways, for example PINK1, which is eliminated in
Figure 4. Functional Studies of APOPT1
(A) Immunoblot analysis of fibroblasts
stably expressing APOPT1-HA. No HA-
immunoreactive material, visualized using
a specific anti-HA antibody (a-HA, Roche),
is present in naive conditions, whereas two
HA-immunoreactive bands are detected
under exposure of the cells to the protea-
some inhibitor MG-132. Tubulin and
SDHB, immunovisualized by specific anti-
bodies (a-TUB, Sigma-Aldrich; a-SDH30,
Mitoscience), are used as loading controls.
(B) The anti-HA immunoreactive bands
obtained as in (A) (arrows) have electro-
phoretic mobility identical to the in vitro
translated cDNAs corresponding to the
predicted precursor (prec) and mature
(mat) APOPT1-HA protein species, synthe-
sized using the TNT Transcription-Transla-
tion System kit (Promega). The in vitro
translated products are specific, as no
anti-HA immunoreactive material is visualized in the prereaction reticulocyte lysate (ret). Note that the panels are from the same filter,
but different exposure times were used to better visualize the bands.
(C) Anti-HA immunoreactive bands corresponding to the precursor and mature APOPT1 species are detected in fibroblasts exposed to
H2O2. Note that the upper band, corresponding to the precursor APOPT1-HA species, is present in the sample collected 8 hr after the
exposure to H2O2, whereas only the mature species is detected in samples collected at 24 and 48 hr, suggesting that over time the pre-
cursor APOPT1-HA species has been translocated across the inner mitochondrial membrane and quantitatively processed into the
mature species by cleavage of a 39 amino acid N-terminal MTS.
(D) ROS detection by dichlorofluorescein (DCHF, Invitrogen) fluorescence on control (Ct) and individual S2 fibroblasts in basal and
oxidative stress conditions. Note that naive individual S2 fibroblasts show significantly higher levels of DCHF fluorescence under expo-
sure to 100 mM and 1 mM H2O2. The levels of DCHF fluorescence are significantly lower in APOPT1-HA-expressing individual S2 fibro-
blasts. Bars represent standard deviations. The p values were obtained by unpaired, two-tail Student’s t test.bioenergetically proficient mitochondria, but is stabilized
by the dissipation of the mitochondrial membrane poten-
tial.27 In addition, an analogous mechanism applies to
other important metabolic switch systems, such as the
hypoxia program induced by HIF-1.28
Although COX deficiency is the biochemical hallmark of
APOPT1mutant subjects, nomechanistic link is known be-
tween APOPT1 and cIV assembly or stability. Interestingly,
a connection between apoptosis and increased ROS pro-
duction has been suggested to play an important role in
the pathophysiology of mitochondrial diseases associated
with COX deficiency.29,30 We showed that the expression
of wild-type APOPT1 in mutant fibroblast cells led to an in-
crease in the amount of COX and a reduction of ROS pro-
duction to normal levels. However, shRNA-mediated stable
downregulation of APOPT1 expression in human myo-
blasts or immortalized fibroblasts failed to either impair
COX activity or increase ROS production, but was associ-
ated with markedly attenuated cell growth up to arrest of
proliferation and cell degeneration. This dramatic cell
growth phenotype is likely to be an acute phenomenon,
consequent to the sudden suppression of APOPT1 expres-
sion, since it was not observed in mutant fibroblasts, i.e.,
in a chronic condition of APOPT1 deprivation. One possi-
bility is that shRNA-treated cells that do develop COX
deficiency are rapidly eliminated, determining growth
impairment, whereas the surviving cells are selected for
COX proficiency.
In conclusion, APOPT1 mutations are responsible for
infantile or childhood-onset mitochondrial disease distin-The Americanguished by the combination of profound, generalized
deficiency in COX activity and amount, a peculiar neuroi-
maging presentation of cavitating leukodystrophy with
posterior cerebral predominance, and a peripheral neurop-
athy. APOPT1 is an elusive mitochondrial protein, which
appears to be actively eliminated by proteasome degrada-
tion in normal conditions of cell culturing, but be stabilized
by, and participate in, a stress-induced program related to
ROS production. Several questions remain open, including
the high clinical variability found in mutant subjects.
Future work is warranted to better characterize the condi-
tions triggering the stabilization of APOPT1, to clarify its
role in mitochondrial homeostasis, and to elucidate the
mechanistic link between its impairment and a structural
and functional defect of COX activity.Supplemental Data
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